Georgios Chatzikonstantinou1, Nikolaos Zamboglou2, Claus Rödel2, Eleni Zoga3, Iosif Strouthos4, Saeed Ahmed Butt5, Nikolaos Tselis2. 1. Department of Radiotherapy and Oncology, J. W. Goethe University of Frankfurt, Frankfurt am Main, Germany. Georgios.Chatzikonstantinou@kgu.de. 2. Department of Radiotherapy and Oncology, J. W. Goethe University of Frankfurt, Frankfurt am Main, Germany. 3. Department of Radiotherapy and Oncology, Sana Klinikum Offenbach, Offenbach am Main, Germany. 4. Department of Radiotherapy and Oncology, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany. 5. Department of Medical Physics and Engineering, Sana Klinikum Offenbach, Offenbach am Main, Germany.
Abstract
PURPOSE: To review the current status of interstitial high-dose-rate brachytherapy as a salvage modality (sHDR BRT) for locally recurrent prostate cancer after definitive radiotherapy (RT). MATERIALS AND METHODS: A literature search was performed in PubMed using "high-dose-rate, brachytherapy, prostate cancer, salvage" as search terms. In all, 51 search results published between 2000 and 2016 were identified. Data tables were generated and summary descriptions created. The main outcome parameters used were biochemical control (BC) and toxicity scores. RESULTS: Eleven publications reported clinical outcome and toxicity with follow-up ranging from 4-191 months. A variety of dose and fractionation schedules were described, including 19.0 Gy in 2 fractions up to 42.0 Gy in 6 fractions. The 5‑year BC ranged from 18-77%. Late grade 3 genitourinary and gastrointestinal toxicity was 0-32% and 0-5.1%, respectively. CONCLUSIONS: sHDR BRT appears as safe and effective salvage modality for the reirradiation of locally recurrent prostate cancer after definitive RT.
PURPOSE: To review the current status of interstitial high-dose-rate brachytherapy as a salvage modality (sHDR BRT) for locally recurrent prostate cancer after definitive radiotherapy (RT). MATERIALS AND METHODS: A literature search was performed in PubMed using "high-dose-rate, brachytherapy, prostate cancer, salvage" as search terms. In all, 51 search results published between 2000 and 2016 were identified. Data tables were generated and summary descriptions created. The main outcome parameters used were biochemical control (BC) and toxicity scores. RESULTS: Eleven publications reported clinical outcome and toxicity with follow-up ranging from 4-191 months. A variety of dose and fractionation schedules were described, including 19.0 Gy in 2 fractions up to 42.0 Gy in 6 fractions. The 5‑year BC ranged from 18-77%. Late grade 3 genitourinary and gastrointestinal toxicity was 0-32% and 0-5.1%, respectively. CONCLUSIONS: sHDR BRT appears as safe and effective salvage modality for the reirradiation of locally recurrent prostate cancer after definitive RT.
Authors: Paul L Nguyen; Shabbir M H Alibhai; Shehzad Basaria; Anthony V D'Amico; Philip W Kantoff; Nancy L Keating; David F Penson; Derek J Rosario; Bertrand Tombal; Matthew R Smith Journal: Eur Urol Date: 2014-08-02 Impact factor: 20.096
Authors: Greta Meredith; David Wong; John Yaxley; Geoff Coughlin; Les Thompson; Boon Kua; Troy Gianduzzo Journal: BJU Int Date: 2016-09-23 Impact factor: 5.588
Authors: Inga S Grills; Alvaro A Martinez; Mitchell Hollander; Raywin Huang; Kenneth Goldman; Peter Y Chen; Gary S Gustafson Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: Jim Zhong; Finbar Slevin; Andrew F Scarsbrook; Maria Serra; Ananya Choudhury; Peter J Hoskin; Sarah Brown; Ann M Henry Journal: Front Oncol Date: 2021-09-09 Impact factor: 6.244